Weekly FDA Drug Pipeline Calendar (Feb 13 - Feb 17)

Next week big pharma companies such as $Biogen (BIIB.US)$ , $Sage Therapeutics (SAGE.US)$ , andIronwood $Ironwood Pharmaceuticals (IRWD.US)$ will release their quarterly earnings report.

$Hillstream BioPharma (HILS.US)$ shares continued to trade up this week after it announced initial results from a study conducted of HSB-1216 with pembrolizumab in KRAS G12C-mutated non-small cell lung cancer cells, calu-1. Data reported significantly greater tumor inhibition. Shares closed the week up 33% at $1.59.

$Sintx Technologies (SINT.US)$ announced a stock offering of 2,150,000 units this week, each with one Class C and D warrant. The units were priced at $5.60 each, with a gross profit of $12 million expected. The stock finished the week down 69% at $2.72.

$Revelation Biosciences (REVB.US)$ reported pre-clinical data of REVTx-300 in a model of acute and chronic kidney disease. The data showed that there was a significant reduction in circulating transforming growth factor- in a dose-dependent manner when compared to the positive control group. The public offering of 3,225,000 shares of stock and warrants was priced at $4.83 per unit. The total gross proceeds are expected to be around $15.6 million. The stock finished the week down 67% at $2.85.

$Omeros (OMER.US)$ received a milestone payment this week of $200 million from Rayner Surgical under the 2021 Asset Purchase Agreement. Shares closed the week up 23% at $5.05